Fate Therapeutics INC 8-K filings

Fate Therapeutics announced second quarter 2026 financial results, highlighting progress in its CAR T-cell therapy pipeline, including patient dosing in a Phase 2 trial for lupus nephritis and FDA clearance for a new autoimmune trial.

Fate Therapeutics' stockholders approved an amendment to the 2022 Stock Option and Incentive Plan, increasing available shares by 7 million, and ratified the appointment of Ernst & Young LLP.

Fate Therapeutics released an updated corporate presentation detailing clinical progress in its off-the-shelf CAR T-cell therapy pipeline for autoimmune diseases and cancer.

Fate Therapeutics announced first quarter 2026 financial results, highlighting an extended operating runway into 2028 due to a 20% reduction in operating expenses.

Fate Therapeutics announced its Q4 and full year 2025 financial results, highlighting significant clinical advancements in off-the-shelf CAR T-cell therapies and a strong cash runway.

Fate Therapeutics reports Q3 2025 financial results, highlighting clinical advancements in autoimmune and oncology programs and a projected operating runway through year-end 2027.

Fate Therapeutics announced promising Phase 1 clinical data for its off-the-shelf CAR T-cell therapy, FT819, in patients with moderate-to-severe systemic lupus erythematosus, demonstrating immune remodeling and durable responses.

Fate Therapeutics announced the appointment of Kamal Adawi as Chief Financial Officer and a reduction in its Board size following two voluntary resignations.

Fate Therapeutics announced Q2 2025 financial results, a corporate restructuring including a 12% workforce reduction, and clinical advancements in its iPSC-derived CAR T-cell programs, extending its cash runway through 2027.

Fate Therapeutics, Inc. has filed an amendment to its recent 8-K report, formally disclosing its decision to hold non-binding advisory votes on executive compensation annually, aligning with stockholder approval.

Fate Therapeutics, Inc. announced the appointment of Matthew Abernethy to its Board of Directors, the departure of Timothy P. Coughlin, and stockholder approval to increase authorized common stock and expand its equity incentive plan.

Fate Therapeutics reports first quarter 2025 financial results and provides business updates, including positive developments in its FT819 program for autoimmune diseases and progress in its iPSC-derived CAR T-cell pipeline.

Fate Therapeutics announces promising clinical updates for its FT819 and FT825 cell therapy programs, along with a solid cash position to extend operations through 2026.

Fate Therapeutics has announced the retirement of its CEO, J. Scott Wolchko, and the appointment of Bahram Valamehr as his successor, along with a strategic advisory agreement with the former CEO.

Biopharmaceutical company Fate Therapeutics announced that President and CEO Scott Wolchko will retire on December 31, 2024, and will be succeeded by current President of Research and Development, Bob Valamehr, effective January 1, 2025.

Fate Therapeutics announced positive initial clinical data from its Phase 1 studies for multiple cell therapy candidates and reported a strong cash position of $331 million.

Fate Therapeutics has updated its director and officer indemnification agreement to provide greater clarity and protection, including enhanced change of control provisions and expense coverage.

Fate Therapeutics announced its second quarter 2024 financial results and provided updates on its ongoing clinical trials for various cell therapy product candidates.

Fate Therapeutics has appointed Dr. Neelufar Mozaffarian to its Board of Directors, increasing the board size to ten members.

Fate Therapeutics has amended its certificate of incorporation to limit the personal liability of its officers, effective June 7, 2024.

Fate Therapeutics has appointed its CEO, J. Scott Wolchko, as interim CFO following the resignation of Edward J. Dulac III, and has also increased the number of shares available under its 2022 Stock Option and Incentive Plan.

Fate Therapeutics' Chief Financial Officer, Edward J. Dulac III, has resigned, and the company's CEO, J. Scott Wolchko, will assume the CFO role effective June 14, 2024.

Fate Therapeutics announced its Q1 2024 financial results and highlighted progress in its clinical programs, including the first patient treated with FT819 for lupus and the initiation of a conditioning-free treatment arm for FT522.

Fate Therapeutics has dosed the first patient in its Phase 1 autoimmunity study of FT819 and presented encouraging translational data for both its FT819 and FT522 programs at the ASGCT annual meeting.

Fate Therapeutics has successfully priced a $100 million capital raise through a public offering of common stock and a concurrent private placement of pre-funded warrants.

Fate Therapeutics announced its fourth quarter and full year 2023 financial results, highlighted by progress in its iPSC-derived cell therapy programs and a $7.9 million grant from CIRM.